← Entheocast Week 23 — June 7–13, 2026
Generated 2026-06-07 · raw JSON
New this week: 291
Total entries: 291
Compounds represented: 9
New This Week (291 entries)
Psilocybin
Prenatal stress, excitatory-inhibitory imbalance, and ADHD risk: a hypothesis-driven perspective on psilocybin-induced neuroplasticity. (Meta-analysis)Changes in anxiety, quality of life, and functioning following psilocybin-assisted therapy in veterans with treatment-resistant depression. (Phase 2)Correction to: Preliminary Evidence of Sleep Improvements Following Psilocybin Administration, and their Involvement in Antidepressant Therapeutic Action. (Phase 2)Inaugural year of regulated psilocybin services in Oregon: safety, motivations, and utilization. (Phase 2)Time to embrace the whole: considering the replacement of psilocybin with Psilocybe spp. in psychedelic research and therapy. (Phase 2)Psilocybin Decreases Preference for Large Rewards Accompanied by Increased Activity of Parvalbumin Neurons With Perineuronal Nets in the Medial Prefrontal Cortex. (Phase 2)A spatiotemporal gating hypothesis for psilocybin plasticity: reconciling the 5-HT₂A-TrkB mechanistic paradox. (Phase 2)Effects of psilocybin on sleep quality and brain microstructure in chronic cluster headache. (Phase 2)Correction: Catatonia Associated With First-Time Psilocybin Exposure: A Case Report. (Phase 2)Blinding integrity in psychedelic research: Evidence from a comparative randomized controlled trial of psilocybin, MDMA, and methylphenidate in healthy volunteers. (Phase 2)Psilocybin-induced neurocardiogenic syncope: a case report. (Phase 2)Long-Term Efficacy of Psilocybin with Adjunct Psychotherapy in Treatment-Resistant Major Depression (EPIsoDE): 6- and 12-Month Naturalistic Follow-Up of a Phase 2b Trial. (Phase 2)Psilocybin in Older Adults: Therapeutic Opportunities in Inflammation-Driven Disorders of Aging-From Depression to Neurodegeneration. (Meta-analysis)Does Psychological Flexibility Correlate with Mystical Experiences: A Machine Learning Approach Including State of Surrender, Near-Death Experiences, and Psilocybin Consumption. (Phase 2)Epigenome-wide association study of psilocybin-induced methylome changes in alcohol use disorder. (Phase 2)Psilocybin induces stereotyped movements and reduces defensive responding in planarians through 5-hydroxytryptamine mechanisms. (Phase 2)Psilocybin modulates social behaviour in male and female mice in a time-dependent manner. (Phase 2)The magic of mushrooms: psilocybin influences behavior in the mangrove rivulus fish, Kryptolebias marmoratus. (Phase 2)PsiConnect: Multimodal Neuroimaging of Context-Dependent Brain and Behaviour Dynamics under Psilocybin. (Phase 2)Psychedelic exposure in pregnancy: a scoping review to inform perinatal drug safety and clinical counseling (Meta-analysis)Psychedelic-assisted pharmacotherapy: clinical applications and regulatory considerations (Meta-analysis)Blinding Integrity in Psychedelic Randomized Clinical Trials (Meta-analysis)Psilocybin-assisted Therapy for Post-Traumatic Stress Disorder in Survivors of Intimate Partner Violence (Phase 2, University of Calgary, n=76, recruiting)Psilocybin as a Novel Therapy for Residual Anhedonia (Phase 1, NYU Langone Health, n=90, recruiting)The Efficacy of Psilocybin Therapy for Depression in Parkinson's Disease (Phase 2, Yale University, n=40, recruiting)The Effects of Psilocybin in Healthy Volunteers: Psychological, Biochemical and Electrophysiological Biomarkers. (Phase 1, Gabriella Gobbi, n=50, recruiting)Group Retreat Psilocybin Therapy for Healthcare Clinicians With Loss of Meaning in Their Work and Symptoms of Depression (Phase 2, University of Washington, n=72, recruiting)Psilocybin for Prolonged Grief Disorder (Observational, University of Virginia, n=12, recruiting)Psilocybin Assisted Psychotherapy for Treatment Resistant Depression and Co-occurring Substance Use Disorder (Phase 1, Indiana University, n=50, recruiting)RCT of Psilocybin-assisted CBT for Depression (Phase 1, University of California, Los Angeles, n=50, recruiting)Psilocybin-Assisted Therapy for the Treatment of Major Depressive Disorder in Patients With Non-Small Cell Lung Cancer (Phase 2, Alan Davis, n=10, recruiting)Safety and Tolerability Trial of Psilocybin in Healthy Older Adults (Phase 1, University of Colorado, Denver, n=40, recruiting)Group Psilocybin-Assisted Therapy for Post-Traumatic Stress Disorder (Phase 1, University of New Mexico, n=36, recruiting)UCSF Psilocybin Clinical Trials — San Francisco Bay Area (other, UCSF)Psilocybin Patent Tracker (other)BREAKING: Second Positive Phase 3 for Compass' Psilocybin, Though Modest Magnitude Raises Questions (Phase 3, COMPASS Pathways) — COMPASS Pathways reported a second positive Phase 3 trial for its synthetic psilocybin (COMP360) in treatment-resistant depression, though the modest magnitude of effect and adverse event profile raised questions among analysts and investors.Compass Pathways Announces Second Quarter 2025 Financial Results and Business Highlights (News, Compass Pathways plc, active) — Compass Pathways reported positive primary endpoint results from its first COMP360 Phase 3 trial (COMP005) in treatment-resistant depression, showing a highly statistically significant and clinically meaningful reduction in depression at 6 weeks with no unexpected safety findings. The second Phase 3 trial (COMP006) continues to enroll, with 26-week data expected in late 2026.Johns Hopkins Center for Psychedelic and Consciousness Research (Observational, Johns Hopkins Center for Psychedelic and Consciousness Research, active) — The center focuses on exploring psilocybin for various psychiatric and behavioral disorders, with demonstrated safety in regulated settings and potential benefits for anxiety in cancer patients and smoking cessation.
MDMA
Comparison of acute effects of 3,4-methylenedioxymethamphetamine (MDMA) with and without a supplemental booster dose in healthy participants: a double-blind, randomized, placebo-controlled, crossover study. (Phase 2)From therapeutic promise to evidentiary discipline: Reassessing MDMA-assisted psychotherapy for posttraumatic stress disorder. (Phase 2)Differential alterations in peripheral tryptophan pathways in methamphetamine versus MDMA users are linked to their contrasting psychiatric symptoms. (Phase 2)MDMA-assisted Therapy for Fibromyalgia (Observational, Spaulding Rehabilitation Hospital, n=20, recruiting)MDMA-Assisted Therapy for Veterans With PTSD and Alcohol Use Disorder (Phase 2, VA Office of Research and Development, n=80, recruiting)A Multi-Site Study of MDMA-Assisted Psychotherapy for Eating Disorders (Phase 2, Resilient Pharmaceuticals, completed)MDMA-Assisted Therapy for Mental Healthcare Providers (Phase 1, Rachel Yehuda, n=30, recruiting)MDMA Trials for PTSD in Soldiers, What to Know Now (News, active) — The FDA has reviewed Phase 3 trial data; as of 2026, MDMA has not been approved for general clinical use. The VA does not currently offer MDMA-assisted therapy as a standard treatment, though clinical trials continue through approved research sites.VA clinical trial on psychedelic-assisted therapy gives Missouri lawmakers hope (Phase 2, U.S. Department of Veterans Affairs, n=80, recruiting) — The VA launched a new randomized controlled trial of MDMA-assisted therapy for PTSD and alcohol use disorder in U.S. veterans; it will enroll approximately 80 veterans and compare outcomes between those receiving MDMA-assisted therapy and a control group.VA launches MDMA-assisted mental health therapy trial (Phase 2, U.S. Department of Veterans Affairs, n=80, recruiting) — The trial was announced to evaluate safety and efficacy of MDMA-assisted therapy for PTSD and alcohol use disorder in U.S. Veterans. It will enroll approximately 80 Veterans and compare outcomes between MDMA-assisted therapy and identical psychotherapy with an active placebo.Australia’s Largest Private Health Insurer Commits $10M to Fund MDMA Therapy for PTSD in First-of-its-Kind Program (News, Medibank) — Medibank committed AUD $10 million to fund MDMA-assisted therapy for PTSD and a long-term outcomes and health economics study led by Australian National University researchers, partnering with Emyria to pilot the program.Confirmatory Phase 3 Trial of MDMA Therapy for PTSD is “Successful”, Says MAPS (Phase 3, MAPS, n=104, completed) — Results confirmed prior positive findings from MAPP1; no serious adverse events were observed. More than half of participants identified as people of color.Vibe Check: FDA Set to Decide Future of MDMA-Assisted Therapy This Week (News, Lykos Therapeutics) — Pending FDA decision on New Drug Application (NDA) for MDMA-assisted therapy for PTSD with target PDUFA date of August 11, 2024; three possible outcomes discussed: approval, Complete Response Letter, or delay.Breaking Trauma: Mechanisms of MDMA-Assisted Psychotherapy for PTSD (Observational)
Ketamine
Effect of intraoperative ketamine on pain, opioid use, and psychological recovery in orthopedic trauma patients (KOPM trial): protocol for a randomized, single-blind trial. (Phase 2)Esketamine alleviates trigeminal neuralgia and anxiety-like behaviors in mice by inhibiting RIPK1/RIPK3/MLKL-mediated necroptosis. (Phase 2)Response to: Commentary on "Long-term treatment with esketamine nasal spray in patients with treatment resistant depression: Results from the ESCAPE-LTE study". (Phase 2)Structural Neurotoxic and Neuroprotective Effects of Ketamine and Esketamine in Preclinical and Human Studies: A Systematic Review. (Phase 2)The role of esketamine in enhancing postoperative recovery and pain management in laparoscopic surgery: a meta-analysis of randomised controlled trials. (Meta-analysis)Multimodal opioid-free anesthesia containing esketamine versus opioid-based anesthesia: a systematic review and meta-analysis. (Phase 2)In situ nasal gel loaded with Lactoferrin-Coated Brexpiprazole nanostructured lipid carriers for Schizophrenia: Cross-Species validation in Ketamine-Induced rat and zebrafish models. (Phase 2)A scalable opto-electrochemical sensor for salivary and urinary detection of ketamine: towards selective assay by naked-eye. (Phase 2)The Comparative Sensitivity to Ketamine-Induced Neuronal Death in Juvenile and Adult Rats. (Phase 2)Association of Esketamine use with mortality and clinical outcomes in patients with cancer-related depression: A target trial emulation. (Phase 2)A pilot randomized trial of ketamine for suicidal ideation in a pediatric emergency department. (Phase 2)Deep learning guided propofol ketamine dosing and inflammation trajectories in elderly burns. (Phase 2)Comment on: prophylactic esketamine to reduce postpartum depression in primiparae. (Phase 2)Reply to: prophylactic esketamine to reduce postpartum depression in primiparae: A multicentre, double-blind, randomised clinical trial. (Phase 2)Prophylactic esketamine to reduce postpartum depression in primiparae: A multicentre, double-blind, randomised clinical trial. (Phase 2)Efficacy and safety of ketamine in total hip arthroplasty: a systematic review. (Phase 2)Increasing dose of esketamine for supplemental analgesia after complex spinal fusion surgery: a randomized and double-blind trial. (Phase 2)Unveiling the role of single versus repeated low-dose ketamine in attenuating doxorubicin-induced chemobrain and depression in rats: differential modulation of neuroinflammation, phosphorylated GLT-1, SERT, DAT, and BDNF/TrkB signaling. (Phase 2)Ciprofol-Esketamine Versus Ciprofol-Remifentanil in Hysteroscopic Endometrial Polypectomy: A Randomized Controlled Trial. (Phase 2)Sedative Effects of Dexmedetomidine and Ketamine or Dexmedetomidine and Midazolam on Tear Production, Ocular Perfusion Pressure and Pupil Diameter in Rabbits. (Phase 2)Go With the Flow: MOR(E) to Ketamine Than NMDA Receptor Antagonism. (Phase 2)Mu-Opioid Signaling Engagement as a Candidate Maintenance Mechanism for Prolonging Ketamine's Antisuicidal Effects. (Phase 2)Safety and tolerance of oral ketamine: A systematic review. (Meta-analysis)Beyond the High: A Narrative Review of the Chronic Complications of Recreational Ketamine Use. (Meta-analysis)Intraoperative low-dose ketamine for postoperative pain outcomes in opioid-naïve patients: a systematic review and meta-analysis. (Meta-analysis)The Use of Ketamine for Depression in Cancer Patients: A Systematic Review of Efficacy, Safety, and Clinical Applications. (Meta-analysis)Meta-Analysis: Ketamine Injections Rapidly Reduce Major Depressive Episode Symptoms. (Phase 2)Intramuscular Ketamine Pharmacokinetics in Humans: A Review. (Meta-analysis)Conscious Sedation with Ketamine-Dexmedetomidine Versus Midazolam-Pentazocine in Enhancing Minor Oral Surgery Experience: A Parallel Arm Randomized Clinical Trial. (Phase 2)A Method for Measuring Dissociative Effects of Sub-Anesthetic Doses of Ketamine in Juvenile Female Rats. (Phase 2)Toward Integrating Intranasal Esketamine with Traumatic-Memory Psychotherapy in Treatment-Resistant Depression: A Narrative Review and Feasibility-Oriented Protocol Proposal. (Meta-analysis)Effects of a Single Sub-Anesthetic Dose of Ketamine in Tobacco Use Disorder: An Active-Placebo, Randomized Crossover Study. (Phase 2)Study protocol for the effect of intraoperative subanaesthetic dose esketamine on the incidence of postoperative depressive symptoms in patients with breast cancer: a multicentre, prospective, randomised controlled trial. (Phase 2)Neurodevelopmental and behavioral effects of early-life esketamine hydrochloride exposure in zebrafish (Danio rerio). (Phase 2)Building an opportunity to improve statusepilepticus treatment through EEG monitoringand the use of ketamine. A case report. (Phase 2)Early suicidal ideation change and suicidality-associated emergency department utilization after ketamine or esketamine treatment in treatment-resistant depression. (Phase 2)Pharmacological modulation of anxiety-like behavior by flumazenil, midazolam, and ketamine in rats: Evidence from aversive ultrasonic vocalizations and elevated plus maze. (Phase 2)Efficacy and Safety of Esketamine in Total Hip and Knee Arthroplasty: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. (Meta-analysis)Corrigendum to "Intranasal esketamine in treatment-resistant depression: long-term dosing patterns and clinical outcomes in a 5-year observational study". (Phase 2)Ketamine-based ICU sedation and patient-centered outcomes: A systematic review and meta-analysis of mechanical ventilation duration, ICU length of stay, and delirium. (Phase 2)Retraction notice to "Changes in information integration and brain networks during propofol-, dexmedetomidine-, and ketamine-induced unresponsiveness" [Br J Anaesth 132 (2024) 528-540]. (Phase 2)Clinical utilization and timing of ketamine in pediatric status Epilepticus: a national cross-sectional survey of physicians in Türkiye. (Phase 2)Efficacy and Safety of Adjunctive Therapy Using Single High-Dose S-Ketamine Infusion for Fibromyalgia: A Multicenter, Prospective, Randomized, Controlled, Open-Label, Blinded-Endpoint Study Protocol. (Phase 2)Shorter to be effective: subanesthetic-dose ketamine infusion reduces the global and regional path length of brain functional connectivity in patients with treatment-resistant depression and suicidal ideation. (Phase 2)Simultaneous LC-MS/MS determination of the emerging ketamine analogue 2F-2-oxo-PCPr and related compounds in human hair and application to forensic casework. (Phase 2)A novel sequential ketamine and D-cycloserine/lurasidone therapy for bipolar depression with acute suicidal ideation. (Meta-analysis)Pilot study on esketamine response in treatment-resistant depression: impact of pharmacogenetic, clinical, and demographic variables. (Phase 2)Effect of ketamine intervention on hemodynamic responses in patients with treatment-resistant depression. (Phase 2)Neurometabolic depletion with ketamine during sevoflurane anaesthesia. (Phase 2)Intranasal sufentanil versus ketamine for acute severe traumatic pain in children: protocol for a phase II randomised controlled trial (SUF-KET-PED). (Phase 2)Treatment-emergent psychiatric adverse events in patient-reported outcomes during ketamine use for major depressive disorder: a retrospective analysis. (Phase 2)When Off-Label Ketamine Meets Direct-to-Consumer Telehealth: Liability Risks and Ethical Responsibilities. (Phase 2)Safety and efficacy of esketamine versus remifentanil as adjuncts to propofol sedation in children undergoing haematologic-oncologic procedures in China: a single-centre, randomised, controlled, crossover trial protocol. (Phase 2)Ultrasound Guided Pecs Block and Ketamine Infusion for Preventing Chronic Pain in Patients Undergoing Breast Cancer Surgery (Observational, Aga Khan University, n=120, recruiting)Mystical Experience Induced by Esketamine Treatment: A Real-World Observational Study (Preprint)Racing Beyond Racemic: A Look at Ketamine Drug Development Ahead of atai's PCN-101 Phase 2a Readout (News, atai / Perception Neuroscience, active)What Approval Won’t Solve: Brian Barnett on Ketamine’s Lessons, RVUs, and Scaling Psychedelic Care (News)Therapy or Threat? UK Expert Warns of Rising Ketamine Addiction as Phase 3 Alcoholism Trial Launches (Phase 3, University of Exeter, active) — Phase III trial for ketamine-assisted therapy in alcohol addiction has launched. Professor Celia Morgan of University of Exeter, who has led the world's largest studies of KAT, discusses the therapeutic potential alongside rising concerns about recreational ketamine addiction in the UK.Protocol for intravenous ketamine treatment for patients with therapy-resistant depression (Observational, Østfold Hospital (The Ketamine Unit at DPS Nordre, Østfold Hospital)) — Protocol describing intravenous ketamine treatment program for therapy-resistant depression at Østfold Hospital, including indication criteria (MADRS ≥20, failed ≥2 antidepressants), treatment procedures, dosage, psychotherapeutic integration, and safety monitoring framework. Version 1 dated November 2024.Brain scans reveal how ketamine quickly lifts severe depression (Observational, Yokohama City University Graduate School of Medicine, n=83) — PET imaging with [11C]K-2 tracer showed that ketamine's antidepressant effects in treatment-resistant depression are mediated by dynamic, region-specific changes in AMPA receptor density in the living human brain, with some cortical areas showing increased receptor density and reward-processing regions like the habenula showing reductions.Drug combo is the first to prolong ketamine’s antisuicide effects (other, Stanford Medicine) — A drug combination was found to be the first to prolong ketamine's antisuicide effects, though further research is needed to understand longer term effects and applicability to other types of depression such as bipolar disorder.Is Ketamine Still a Party Drug in 2026? (News, Neuroscience Research Institute) — Article discusses ketamine's dual identity in 2026 as both a continuing recreational/party drug and an established medical treatment for mental health conditions. No specific study results or clinical trial outcomes reported.Evidence and Experience: Samuel Wilkinson on the State of (Es)ketamine Therapy and What Comes Next (News, Yale University, recruiting) — Samuel Wilkinson of Yale is leading a large multi-site, open-label, randomized non-inferiority study comparing IV ketamine to intranasal esketamine (Spravato) for treatment-resistant depression. No comparative outcomes are yet reported; existing observational data suggesting IV ketamine may perform better are limited by non-randomized design and socioeconomic confounding.UCSF Ketamine Clinical Trials — San Francisco Bay Area (other, UCSF) — This is a landing page listing multiple UCSF clinical trials involving ketamine across various conditions including Parkinson's disease, depression, status epilepticus, eating disorders, and methamphetamine use disorder.Extended-release ketamine tablets for treatment-resistant depression: a randomized placebo-controlled phase 2 trial (Phase 2, n=168) — The primary endpoint was met; the 180 mg extended-release ketamine tablet group showed a least square mean difference in MADRS score of -6.1 (95% CI 1.0 to 11.16, P = 0.019) compared to placebo at 13 weeks. Relapse rates showed a dose response from 70.6% for placebo to 42.9% for 180 mg. The treatment was well tolerated with no blood pressure changes, minimal sedation and dissociation.
Ayahuasca
Not Many Patents Threaten Traditional Knowledge About Ayahuasca (other) — A detailed survey indicates that active patent requests implying undue appropriation of ayahuasca-based traditional knowledge are rare; the article argues that inaccurate or exaggerated information about patent threats spreads alarmism without factual basis and hinders negotiation between Indigenous communities and researchers.Football Player Jordan Poyer Leads the Breath of Life Tour (News, Luminate) — NFL player Jordan Poyer founded Luminate in 2024 and launched the "Breath of Life" tour, a modern ceremonial concert blending breathwork, sound healing, movement, and live music, with MAPS as a founding sponsor. The tour aims to scale access to psychedelic-informed healing modalities.
Other
OPTIMIZING EXTRACTION AND CONCENTRATION METHODS FOR LC-MS/MS ANALYSIS OF VETERINARY PHARMACEUTICALS IN EQUINE-ASSOCIATED ENVIRONMENTAL MATRICES. (Phase 2)Psychometric validation of the French version of the five-dimensional altered states of consciousness questionnaire (5D-ASC) and associated 11 OAV subscales. (Phase 2)High stakes: how legal cannabis pricing impacts the illicit market. (Phase 2)The effect of treatments for postpartum depression on breastfeeding practices: a systematic review and meta-analysis. (Meta-analysis)U.S. Poison Center exposure cases involving marijuana and selected comparator substances. (Phase 2)A cross-national comparison of nonmedical and medical use of psychedelic drugs in the international cannabis policy study. (Phase 2)Genivs Plane Block-A Novel Mix of Regional Blocks for Knee Surgery: Used to Provide Complete Analgesia for Through Knee Amputation With a Continuous Distal Femoral Periosteal Catheter in a Pediatric Patient: A Case Report. (Phase 2)Phylogenomic systematics of Lanmaoa (Boletaceae) reveals cryptic diversity, resolves global evolutionary relationships, and suggests a novel psychoactive lineage. (Phase 2)Inhaled Mebufotenin (GH001) for Adult Patients With Postpartum Depression: A Phase 2a Open-Label Clinical Trial. (Phase 2)Development of a monoclonal antibody-based competitive ELISA for serological detection of lumpy skin disease virus. (Phase 2)Association of multimodal analgesic protocol with postpartum depression incidence and sleep quality in high-risk parturients. (Phase 2)Emergence of synthetic drugs in South America: insights from Brazil, Chile, and Colombia. (Meta-analysis)Substance-induced manic psychosis in which delusions were corroborated by a chatbot - case report. (Phase 2)Classic Psychedelics for Chronic Pain: A Critical Review of the Literature and Practical Advice for Clinicians. (Meta-analysis)Relapse-associated versus relapse-independent progression determines disability trajectories in multiple sclerosis beyond EDSS 3.0. (Phase 2)Child and maternal health outcomes following antenatal exposure to classic psychedelic substances: a systematic review. (Phase 2)Ketaminindusert skade på urinveiene. (Phase 2)Evaluations of nurse managers' work environment: a descriptive study. (Phase 2)Cost-Effectiveness of Universal Newborn Screening and Disease-Modifying Therapies for Spinal Muscular Atrophy in Taiwan. (Phase 2)Locomotor and discriminative stimulus effects of N-cyclohexyl butylone and N-cyclohexyl methylone. (Phase 2)Calcium Signaling Dysregulation as a Convergent Mechanism in Anesthetic-Induced Developmental Neurotoxicity. (Meta-analysis)Dexmedetomidine Dosing Strategies in Sedation and Anesthesia: Pharmacokinetics, Safety, and Clinical Applications - A Narrative Review. (Meta-analysis)Characterizing Antibody-Drug Conjugates with High Molecular Heterogeneity by Native Direct Mass Technology. (Phase 2)Spontaneous and oxytocin-induced contractility of gravid human myometrium with exposure to intravenous anesthetic agents: an ex vivo laboratory study. (Phase 2)SpiralEdge-IoV: secure and adaptive task offloading in internet of vehicles edge computing using logarithmic spiral defense. (Phase 2)Reply to Z Yu and F Qin. (Phase 2)MANDIBULAR BONE MICROARCHITECTURE IN PATIENTS WITH MULTIPLE SCLEROSIS: A FRACTAL ANALYSIS STUDY. (Phase 2)Allergic reactions to anaesthetics in surgery: current challenges and perspectives. (Meta-analysis)Clinical course after cardiac resynchronization therapy in transthyretin amyloid cardiomyopathy receiving disease-modifying therapy. (Phase 2)Relative odds of seizure in emergency department cases of analytically confirmed illicit substance exposure. (Phase 2)The Effect of Vitamin D on the Humoral Immune Response of Calves to the Sheeppox Virus Vaccine. (Phase 2)The antidepressant-like effect of adenosine A(1) receptor over-expression in forebrain neurons does not involve an altered adenosine-mediated control of excitatory synaptic transmission. (Phase 2)Mystery shopper assessments of cannabis retailer practices and regulatory compliance in five U.S. states, 2025. (Phase 2)Sex-specific analysis of early disease course and treatment in a German multiple sclerosis cohort. (Phase 2)Evaluation of various obturation techniques with AH Plus Jet sealer in simulated C-shaped canals. (Phase 2)SMART-MC: Characterizing the Dynamics of Multiple Sclerosis Therapy Transitions Using a Covariate-Based Markov Model. (Phase 2)The prevalence of comorbid migraine in multiple sclerosis: do multiple sclerosis and migraine really coexist? (Phase 2)EXPRESS: Global Increases in Brain Glucose Metabolism Following Acute N,N-Dimethyltryptamine and Harmine Administration in Healthy Volunteers: A randomised [(18)F]FDG-PET Study. (Phase 2)An Update on Somatic Treatments for Suicide Risk. (Meta-analysis)Longitudinal Changes in Transfusion Practice in Myelodysplastic Syndromes: A Population Data-Linkage Study. (Phase 2)Neuropsychological symptoms and subclinical disease activity in multiple sclerosis patients receiving high-efficacy therapy. (Phase 2)Classic psychedelics and personality: An updated systematic review. (Meta-analysis)Treatment persistence in paediatric-onset multiple sclerosis: A Swedish nationwide registry study. (Phase 2)Disease-modifying treatment preferences and decision-making in a multiple sclerosis randomized and observational clinical trial (DELIVER-MS). (Phase 2)Analyzing Global Threat of Lumpy Skin Disease Virus Infection: A Comparative Study of a Time Series Model and Machine Learning Models Across 10 High-Risk Countries. (Phase 2)A more optimistic outlook about disease-modifying therapies and depressive symptoms in multiple sclerosis: A cross-sectional analysis. (Phase 2)Inhibition of compulsive behavior by dextromethorphan on schedule-induced polydipsia in rats: Role of NMDA, sigma-1, and 5-HT receptors. (Phase 2)Early Versus Delayed Treatment with Ocrelizumab: A Multicenter, Real-World Observational Study in People with Multiple Sclerosis. (Phase 2)Psychedelic-induced hypomania and mania: a systematic review and meta-analysis. (Meta-analysis)Differences in how NMDA antagonists modulate negative affective biases in male rats may serve as a predictor of clinical efficacy in major depressive disorder. (Phase 2)A systematic review of the pharmacokinetics of classical serotonergic psychedelic compounds in healthy adult subjects. (Meta-analysis)Retail Availability of Intoxicating Cannabis and Mushroom Products Across Eleven U.S. Cities: Sales Persist Despite Prohibitions. (Phase 2)A conceptual framework based on current and emerging treatments for treatment-resistant depression: mechanistic evolution, clinical evidence, and future directions. (Meta-analysis)Latrepirdine (Dimebon), a potent 5-HT(7) receptor antagonist, modulates stress-mediated behaviors in rodents. (Phase 2)Serum inflammatory cytokines in the progression of depression. (Meta-analysis)Synthetic cannabinoids in human post-mortem samples - ADB-BUTINACA and metabolites in three fatalities. (Phase 2)Same pattern, different result: Algorithmic inconsistency in breath alcohol testing-case reports. (Phase 2)The Serotonin 2B (5-HT2B) Receptor: A Narrative Review of Preclinical and Clinical Evidence on the Safety Considerations and Therapeutic Potential for the Treatment of Depression. (Meta-analysis)Sedative choice alters Klebsiella pneumoniae lung pathogenesis and dissemination. (Phase 2)Potentially Surgical Digestive Complications in Patients With Status Epilepticus: Insights From the ICTAL Registry. (Phase 2)Applying Distinct CDMS Strategies to Observe Nonclassical Virus Capsid Assembly. (Phase 2)Case Report: Oral glutamatergic augmentation for trauma-related disorders with fluoxetine-/bupropion-potentiated dextromethorphan ± piracetam: a four-patient case series. (Phase 2)Studies on Enzymatic Hydrolysis of Psilocin-O-glucuronide for Screening of Psilocin in Human Urine by Liquid Chromatography-Triple Quadrupole Tandem Mass Spectrometry. (Phase 2)From feeding cell to fruiting body: Multidrug transport in the life cycle of Dictyostelium discoideum. (Meta-analysis)Evaluating Antegrade Cerebral Perfusion Flow Rates for Neuroprotection During Hypothermic Circulatory Arrest. (Phase 2)Distinguishing psychomimetic from antidepressant-like effects in mice using molecular and electrophysiological biomarkers. (Phase 2)State-specific inhibition of NMDA receptors by memantine provides insight into NMDAR channel blocker tolerability. (Phase 2)Serum Uric Acid Trajectories in Multiple Sclerosis: A 5-Year Longitudinal Comparison of High- and Moderate-Efficacy Therapies. (Phase 2)Dopamine, glutamate, and gamma-aminobutyric acid: Key hubs in neurotransmitters, signal transduction, and cognitive dysfunction. (Phase 2)Improving access to novel treatments for treatment-resistant depression: The potential role of specialist clinics in Australia. (Phase 2)Dosing Strategies for High-Alert Medications in Obese Pediatric Patients: A Systematic Review. (Meta-analysis)The Monoamine-Glutamate Continuum of Depression: A Neurobiological Framework for Precision Psychiatry. (Meta-analysis)Undernutrition Risk in Community-Living Older Adults: Post-COVID-19 Results from the 2023 U.S. National Survey of Older Americans Act Participants. (Phase 2)Anaesthetic Adverse Events During Propofol-Based Sedation for ERCP: A Real-World Cohort Study. (Phase 2)Predicting Serious Adverse Events, Medication Abuse, Misuse, and Risk of Dependence for Medications with High Dependence Potential: Role of Patient-Reported Factors and Machine Learning Approach. (Phase 2)Multidisciplinary Strategies for Tailored Anesthesia Management in Children Undergoing Radiotherapy. (Meta-analysis)Network dysregulation in depression: A synthesis of HPA Axis, BDNF signaling, and neurotransmitter interactions across multidimensional systems. (Meta-analysis)Effect of dexmedetomidine as an adjuvant in erector spinae plane block on postoperative analgesia in thoracolumbar spine surgery with an opioid free anaesthesia technique: A prospective randomized clinical trial. (Phase 2)Opioid Free anesthesia in cardiac surgery: The OFACAR randomized clinical trial. (Phase 2)Posterolateral Tibial Plateau Fractures-Does Fixation Choice Matter? A Biomechanical Investigation. (Phase 2)Disease-Modifying Therapies in Spinal Muscular Atrophy: Neurodevelopmental and Behavioral Outcomes in the Treatment Era. (Meta-analysis)Sex-Related Differences in Circular RNA Expression in Multiple Sclerosis: A Pilot Study. (Phase 2)Immunogenicity of an Inactivated DIVA Lumpy Skin Disease Virus Vaccine in Guinea Pigs and Lactating Cows, and Its Effects on Cow Lactation. (Phase 2)Toxicokinetic Studies of the Two Stimulants M-ALPHA and N-Methyl-cyclazodone Using In Vitro and In Vivo Tools. (Phase 2)Effects of THC, CBD, and Their Combination on EEG Dynamics in Rats. (Phase 2)Parkinson's disease drug therapies in the clinical trial pipeline: 2015-2024. (Meta-analysis)Prophylactic interventions to prevent rebound pain after peripheral nerve block in adults: a systematic review and network meta-analysis of randomised controlled trials. (Meta-analysis)Evaluation of illicit drug contaminants in seized cannabis in Arizona and California, 2023-2024. (Phase 2)[Mechanism of SMURF2 regulating silicosis-associated epithelial-mesenchymal transition via the TGF-β/Smad signaling pathway]. (Phase 2)[Mechanism of miR-129-5p targeting MAP3K13/p-p38 signaling pathway to inhibit macrophage activation to antagonize silicotic fibrosis in mice]. (Phase 2)Serum and cerebrospinal fluid neuroinflammatory biomarkers and trimethylamine N-oxide: associations with white matter lesion severity. (Phase 2)Psychedelic-assisted therapy: a survey on the clinical methods of Swiss physicians. (Phase 2)Assessing the role of Subacute Encephalopathy with Seizures in Alcoholics (SESA) syndrome in the development of status epilepticus: a case report and systematic review with individual patients' analysis. (Phase 2)Comparison of three contrast agents in the diagnosis of cracked teeth using Cone Beam Computed Tomography (CBCT). (Phase 2)Evaluation and improvement of two European soybean VCU networks. (Phase 2)Pharmacotherapeutic Management of Depression in Patients With Cancer: A Review of Mechanistic and Clinical Evidence. (Meta-analysis)Prevalence of chemical restraint use in hospital care. A consensus and cross-sectional study. (Phase 2)Lenalidomide ameliorates cognitive impairment via putative AChE inhibition: an in silico and in vivo study in a scopolamine-induced cognitive impairment model. (Phase 2)Quantification of Specific Urinary Oligosaccharide Biomarkers for Diagnosis and Treatment Monitoring of Alpha-Mannosidosis. (Phase 2)Morphology of the cervical lamina and spinous processes on CT in northeast China: A retrospective observational study correlating anatomical parameters with cervical spondylosis. (Phase 2)First molecular and phylogenetic study of the bovine lumpy skin disease virus declared in Algeria in 2024. (Phase 2)Lysergic acid diethylamide pretreatment prolongs brain-stimulation induced neural activity changes. (Phase 2)Major depressive disorder is associated with reduced intrinsic connectivity between the bed nucleus of the stria terminalis and ventral striatum. (Phase 2)Coarse-grained modeling of hydrodynamic behavior in DNA synthesis monomers. (Phase 2)Epidemiological Assessment of Lumpy Skin Disease in Cattle: Risk Factors at Farm and Animal Levels in Southern Bangladesh. (Phase 2)Inhibitory Effect of Melatonin on the Proliferation of Breast Cancer Cells MDA-MB-468 by Antioxidants Superoxide Dismutase and Glutathione Peroxidase. (Phase 2)Understanding and evaluation of the concept of "palliative psychiatry" among service users with chronic and treatment-resistant depression: a qualitative study of service user perspectives. (Phase 2)Virtual reality interventions in obesity and eating disorders: a systematic review of biomarker, clinical, and behavioral outcomes. (Meta-analysis)Electroconvulsive therapy in an older patient with recurrent major depressive disorder and a permanent pacemaker: A case report. (Phase 2)Management of Treatment-Resistant Depression: An Updated Narrative Review of Current and Emerging Treatments. (Meta-analysis)Association between VA providers' reported use of care strategies and emergence delirium: a national retrospective cross-sectional survey. (Phase 2)Farmers' knowledge, attitudes, and practices regarding lumpy skin disease in Northern Bangladesh. (Phase 2)New Approach Methodologies and Open Access Tools Help Characterize Risks for DART, DNT, or Endocrine Effects From Exposure to Hallucinogens With Potential Pesticide Contaminants. (Phase 2)Trajectories of processing speed in multiple sclerosis across disease-modifying therapies. (Phase 2)Xanomeline-trospium reverses phencyclidine-induced cognitive deficits through modulation of the gut microbiota-brain axis in mice. (Phase 2)Zebrafish startle habituation: How readout choice influences the interpretation of chemical effects in neurotoxicity screening. (Phase 2)Understanding experiences of psychedelic treatments for eating disorders: a meta-synthesis of qualitative studies. (Phase 2)Condition-Embedded Visible-Infrared image dataset for typical ground features. (Phase 2)Clinical Trial Design and Regulatory Requirements for Artificial Intelligence as a Medical Device: A PRISMA-ScR–Guided Scoping Review of Global Guidance and Evidence (2017–2025) (Meta-analysis)A Randomized Clinical Trial of Kidney Autologous Cell Therapy in Diabetic Kidney Disease. (Phase 2)An updated review of the SMA clinical trial landscape in the United States: Findings from analysis of recruitment targets on ClinicalTrials.gov and a survey of SMA clinical trial sites on factors affecting site capacity and readiness (Meta-analysis)Ultraprocessed foods consumption and risk of preeclampsia: a secondary analysis of the improving mothers for a better prenatal care trial Barcelona (IMPACT BCN) randomized clinical trial (Phase 2)One‐Year Analysis of Clinical and Radiological Outcomes of Two‐Piece Zirconia Compared to Titanium Implants: A Multicenter Prospective Randomized Clinical Trial (Phase 2)Changes in Insulin Resistance with Different Weight Loss Methods in Patients with Type Two Diabetes Mellitus and Hypertension: A Comparative Clinical Trial (Phase 2)Clinical Trial Patient Matching: A Real-Time, Common Data Model and Artificial Intelligence-Driven System for Semiautomated Patient Prescreening in Cancer Clinical Trials. (Meta-analysis)Integrated Clinical Trial and Molecular Profiling Reveals Immune Drivers of Chronic Hand Eczema. (Phase 2)The clinical trial landscape of colorectal cancer liver metastases: profile analysis and target prediction (Phase 2)Vertical skeletal dimension and dentoalveolar changes in extraction versus non-extraction orthodontic treatment in class I malocclusion: a non-randomized clinical trial (Phase 2)Diagnostic performance, safety, and biodistribution of [
68
Ga]Ga-OncoACP3 for PET imaging in prostate cancer: A phase I clinical trial. (Phase 2)Zirconia versus Titanium Implants: 1‐year Prosthetic Outcome of Screw‐Retained Single Crowns in a Randomized Clinical Trial (Phase 2)290 Clinical response to clozapine in Black patients: A secondary analysis of an open-label clinical trial (Phase 2)PhotoBio-HIV: Effects of Vascular Photobiomodulation on Inflammatory and Immunological Biomarkers in People Living with HIV – Study Protocol for a Randomized, Double-Blind, Placebo-Controlled Clinical Trial (Phase 2)Next-Generation Artificial Intelligence in Clinical Trial Design, Conduct, and Analysis: A Paradigm Shift in Clinical Research (Meta-analysis)225 The OSANOVA Clinical Trial: Can a mandibular advancement device spare surgery in severe to moderate OSA? (Phase 2)Prophylactic Intravenous Phenylephrine to Prevent Propofol-induced Hypotension during Induction of General Anaesthesia: A Randomised Clinical Trial (Phase 2)Trueness of Dental Implant Placement Using Dynamic Navigation or Non-Guided Approach by Novice Surgeons: A Randomized, Controlled Clinical Trial. (Phase 2)Analgesic Efficacy of Hyperbaric Ropivacaine versus Hyperbaric Bupivacaine with Fentanyl in Infraumbilical Surgeries under Spinal Anaesthesia: A Double-blinded Randomised Clinical Trial (Phase 2)316 Frontiers Trial Finder: Implementing a mobile platform integrated with a Clinical Trial Management System to enhance accessibility and engagement (Phase 2)A phase 1/2a, multicenter, first-in-human, open-label clinical trial evaluating MDX2004 monotherapy in patients with advanced tumors. (Phase 2)Clinical performance of alkasite and glass-hybrid restorations compared with resin composite in class II cavities: a randomized clinical trial (Phase 2)Efficacy and acceptability of liraglutide for obesity in people with HIV: results of an open-label clinical trial in South Africa (Phase 2)Partially demineralized allogeneic cancellous bone plug versus deproteinized bovine bone mineral for guided bone regeneration: a pilot randomized controlled clinical trial (Phase 2)Ecstasy to Alleviate SEvere Chronic Neuropathic Pain Trial (Phase 2, Unity Health Toronto, n=40, recruiting)Study of Midomafetamine in Healthy Adults (Phase 1, Resilient Pharmaceuticals, n=32, recruiting)Salivary Oxytocin as a Biomarker of Psychedelic Treatment (Observational, University of Geneva, Switzerland, n=80, recruiting)A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend) (Phase 3, Definium Therapeutics US, Inc., n=165, recruiting)Multimodal Pharmacological Study of Clinical Cohorts for Major Depressive Disorder (Observational, Shanghai Mental Health Center, n=130, recruiting)An International Federated Model for Wearable-derived Remote Longitudinal Motor Monitoring in Young Children With Spinal Muscular Atrophy Compared With Healthy Controls: Active-NBS Study (UK) (Observational, University of Oxford, n=90, recruiting)MAPS Celebrates 40 Years at a Defining Moment for Psychedelics (News, Multidisciplinary Association for Psychedelic Studies (MAPS)) — MAPS marks its 40th anniversary, having raised more than $150 million, supported 45 studies, trained 500+ therapists, and contributed to the first NDA submission for a psychedelic-assisted therapy. The organization also notes a new federal Executive Order directing agencies to expand psychedelic research and accelerate regulatory approval.MAPS Welcomes Federal Action to Advance Science-Driven Psychedelic Research and Policy (News, Multidisciplinary Association for Psychedelic Studies (MAPS)) — On April 18, 2026, MAPS issued a statement welcoming an Executive Order directing $50 million in federal funds to accelerate research into psychedelic compounds including ibogaine, psilocybin, LSD, and MDMA for serious mental illness, while emphasizing the need for rigorous science, ethical frameworks, and Indigenous community collaboration.RFK, Jr., puts psychedelics on fast track to FDA review and approval (Regulatory, U.S. Food and Drug Administration) — The FDA announced it is fast-tracking review and approval for three companies studying psilocybin and methylone for depression and PTSD, and approved a phase 1 clinical trial of noribogaine for alcohol use disorder.Why Trump reversed course to fast-track psychedelic drugs for mental healthcare (News) — In April 2026, President Donald Trump signed an executive order to accelerate research into psychedelic drugs for mental illness and issued priority review vouchers to three companies developing psychedelic or MDMA-like therapies (Compass Pathways, Usona Institute, and Transcend Therapeutics) to speed FDA review processes.Studies currently recruiting | Johns Hopkins Medicine Serial Ketamine Infusions as Adjunctive Therapy to Inpatient Care ... MAPS Welcomes Federal Action to Advance Science-Driven Psychedelic Research and Policy (News, Multidisciplinary Association for Psychedelic Studies (MAPS)) — MAPS issued a statement welcoming a federal Executive Order directing $50 million in funding to accelerate research on psychedelic compounds including ibogaine, psilocybin, LSD, and MDMA for serious mental illness, while emphasizing the need for rigorous science, ethical frameworks, and collaboration with Indigenous communities.Psychedelics & Healing Initiative Trends for 2026 (News, Global Wellness Institute) — The article provides an industry overview of psychedelic medicine trends, noting that eight psychedelic candidates have received FDA 'breakthrough therapy' designations and seven have reached FDA Phase 3 trials. It highlights increasing bipartisan political support and FDA receptiveness to novel psychedelic compounds for integration into the healthcare system.Just a moment... (other)Psychedelic Drug Development Tracker (other)